Jesus Herranz

6PUBLICATIONS
85CO-AUTHORS
Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 26, 2026
Sensitivity to endocrine therapy index predicts benefit from weekly adjuvant paclitaxel for hormone receptor-positive breast cancer in the GEICAM/9906 trial.

|Jul 09, 2025
Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial.

Yash N Agrawal, Aranzazu Fernández-Martínez, Miguel Gil-Gil

|Jun 26, 2025
FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial.

Federico Rojo, Clive R Taylor, Carlos Barrios

|Jul 25, 2023
Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients.

Javier Pascual, Miguel Gil-Gil, Paula Proszek

|Feb 07, 2023
CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer.

Ángel Guerrero-Zotano, Stefania Belli, Christoph Zielinski

|Nov 08, 2022
Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine.

Karama Asleh, Ana Lluch, Angela Goytain

Pageof 1

Frequent Collaborators

6 joint publications

Miguel Martin

6 joint publications

Manuel Ruiz-Borrego

5 joint publications

Ángel Guerrero-Zotano

3 joint publications

Christoph Zielinski